GlucoFIX : ANTI-DIABETIC FORMULATION FROM ALBIZIA MYRIOPHYLLA

TECHNOLOGY DESCRIPTION
This technology is a formulation used for lowering of blood sugar levels which contains an effective concentration of *Albizia myriophylla* or tebu gajah bark extract. This formulation can be supplemented with virgin coconut oil.

TECHNOLOGY FEATURES
This technology provides an alternative and natural remedy for the treatment of type I and type II diabetes. It is taken orally as compared to insulin which is administered subcutaneously. It also does not cause liver and kidney damage as compared to current anti-diabetic medication and helps to improve the health of liver and kidney. This technology also able to increase the body weight of diabetes patients, due to its effect in controlling muscle wasting.

ADVANTAGES
- Alternative remedy for type I and type II diabetes
- Can be taken orally
- Does not cause liver and kidney damage
- Improve the health of liver and kidney

INDUSTRY OVERVIEW
Prospects: Patients with Type 2 Diabetes

The global market for diabetes management products currently stands at USD41 billion and is estimated to grow to over USD114 billion by 2018. Oral anti-diabetics (OADs) were most commonly used for type 2 diabetes (T2DM) patients as an adjunct to healthy diet and regular exercises. In Malaysia, there were 657,839 patients registered in the National Diabetes Registry (NDR) at the end of December 2012, of which 653,326 were diagnosed with T2DM. Among the various classes of OAD, metformin and sulphonylureas were the most common OAD prescribed with 82.5% and 56.9% of patients on this treatment respectively. The existing leading products for OAD drugs in major country markets include Januvia, Galvus, Byetta and Actos. With the significant prevalence of T2DM, the global revenue earned from drugs sales to treat this disease was approximately USD36.89 billion in 2012 and it is expected to be increased to approximately USD68.42 billion by 2017.